Begum MN, Mahtarin R, Islam MT, Antora NJ, Sarker SK, Sultana N, et al
Value Proposition 8
The trial to examine the efficacy of the drug for obesity started with the injection of 0.25mg of semaglutide weekly for the first 4 weeks, with the dose increased every 4 weeks to reach the maintenance dose of 2.4mg weekly by week 16 (lower maintenance doses were permitted if participants had unacceptable side effects with the 2.4mg dose)
Insurance coverage for weight loss drugs remains highly variable and typically requires prior authorization and a BMI threshold
Then support recovery with hydration, sleep, and reasonable fuel
Chronic pharmacologic glucagon receptor activation adds something else: it appears to raise energy expenditure and tilt the liver toward burning fat rather than building it